Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET

Company Participants

Ryan Asay - Vice President of Corporate Affairs

David Meek - CEO

James Christensen - Chief Scientific Officer

Ben Hickey - Chief Commercial Officer

Vickie Reed - CAO

Daniel Faga - Chief Commercial Officer

Chuck Baum - President, Founder and Head of R&D

Charles Baum -

Conference Call Participants

Tyler Van Buren - Cowen

Neil Carnahan - Stifel

Gena Wang - Barclays

Jonathan Miller - Evercore

Evan Seigerman - BMO Capital Markets

Michael Ulz - Morgan Stanley

Carly Kenselaar - Citi

Andrew Berens - SVB Securities

Jay Olson - Oppenheimer

Silvan Tuerkcan - JMP Securities

Maurice Raycroft - Jefferies

Operator

Good afternoon, and welcome to the Mirati Therapeutics First Quarter 2022 Earnings Call. My name is Kevin, and I will be the operator for today's call. [Operator Instructions]

It is my pleasure to introduce Ryan Asay, Vice President of Corporate Affairs at Mirati. Ryan, you may begin the call.

Ryan Asay

Thank you, Kevin. Welcome, everyone, to this afternoon's call. Joining me on the call today from a couple of different locations are David Meek, Mirati's Chief Executive Officer; Dr. Chuck Baum, Mirati's President, Founder and Head of Research and Development; Dr. Jamie Christensen, Mirati's Chief Scientific Officer; and Vickie Reed, Mirati's Chief Accounting Officer. Ben Hickey, Mirati's Chief Commercial Officer, is also with us and will be available for the Q&A portion of the call.

Please note that this conference call will include forward-looking statements. Because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Form 10-Q that are filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended March 31, 2022, and recent corporate updates. This press release is available on the Investors section of our website at mirati.com.

With that, Dave, I'll turn the call over to you.

David Meek

Thank you, Ryan. Good afternoon, and thank you for joining us today. On this afternoon's call, I will provide initial remarks before turning to Chuck to share an update on our clinical development programs to Jamie to comment on our preclinical portfolio and Vickie to summarize our first quarter financial results. I will then provide a few concluding remarks before taking your questions.